Skip to content
Decision-ready map
• Therapy goal: light aims to improve symptoms or healing
• Key risk: unintended heating or pigment changes
• Why skin tone matters: melanin absorbs light and can raise temperature
• Your levers: clear consent + stop rules + follow-up
(1) What it is
Many health studies and clinics use light-based therapies—PBM, lasers, IPL, or phototherapy—to help with pain, wound healing, inflammation, skin conditions, or cosmetic concerns. These therapies deliver light at specific wavelengths and doses. Most sessions are safe when used correctly, but side effects can include warmth, redness, blistering, or changes in skin color. Skin tone can sometimes influence how much light is absorbed and how much skin heats up.
(2) Who it helps
This brief supports patients and community members participating in research studies or considering treatment who want to understand safety, fairness, and what questions protect them.
(3) What evidence exists
A 2025 retrospective cohort study reported darker skin color was associated with higher photosensitivity and higher risk of heating/thermal injury during a dual-wavelength low-power laser protocol, with substantially higher odds of clinically visible thermal injury in that dataset (https://doi.org/10.1111/phpp.70042). Dermatology reviews acknowledge that people with more skin pigment can be more vulnerable to burns or pigment changes if device settings are not chosen carefully (https://doi.org/10.4103/ijdvl.IJDVL_88_17). IPL complications reviews list burns and pigmentary changes and emphasize the importance of correct settings and technique (https://doi.org/10.1002/der2.57). The FDA publishes guidance for PBM devices describing expectations for testing and labeling when devices are marketed with medical purposes (FDA webpage).
(4) Translation barriers
Patients may hear “it’s just light, so it’s harmless,” but safety depends on dose, device quality, and tailoring. Studies and clinics may not measure skin tone consistently, which slows learning about best settings for different people. Home-use products can be marketed with vague claims without clear stop rules or follow-up guidance.
(5) Equity/safety checks
Before enrolling or starting treatment, ask what safety steps are taken for different skin tones. During treatment, report heat or pain immediately; protocols should include a stop rule when discomfort exceeds what was explained in consent. Ask how settings are chosen for your skin and what follow-up is planned to check for delayed blistering or pigment change.
(6) Decision questions
• What device model and protocol parameters are used (wavelength, time, cooling)?
• Has the protocol been studied across a range of skin tones, and will safety outcomes be reported by group?
• What should you expect to feel, and what symptoms require stopping or medical review?
• If you have a side effect, how is it treated and reported?
(7) Practical next steps
Request a plain-language information sheet with benefits, risks, and what to do if you experience heat/pain or delayed skin changes. If in research, ask whether the study is designed to learn about safety for diverse skin tones. After sessions, monitor for delayed blistering or pigment change and contact the study team promptly.
(8) References
https://doi.org/10.1111/phpp.70042
https://doi.org/10.4103/ijdvl.IJDVL_88_17
https://doi.org/10.1002/der2.57
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/photobiomodulation-pbm-devices-premarket-notification-510k-submissions